September 17, 2019
AIA, the largest public listed pan-Asian life insurance group, yesterday announced in Singapore a new initiative designed to help combat sleep deprivation – a critical health issue in Asia. The initiative has a hashtag called #OneMoreHour, aims to raise awareness about the health benefits associated with getting sufficient sleep.
As part of the initiative, AIA has also introduced updates to its...
July 19, 2019
Much has happened in the healthtech landscape in the Asia Pacific (APAC) region in the first half of 2019 – according to Galen Growth Asia’s latest report for that period, APAC healthtech funding hit $2.5B across 140 deals. In this article, MobiHealth News looks at the healthtech landscape in APAC for the first half of 2019 across three broad areas: healthtech accelerators, notable funding rounds...
May 26, 2019
Last week, AIA, the largest public listed pan-Asian life insurance group, announced a landmark partnership with Medix, a global health management solutions provider that will benefit AIA customers in the Asia Pacific region. Under the expanded regional partnership, building on already successful collaborations between AIA and Medix in Hong Kong and Singapore, AIA and Medix will work together to...
Above photo: Dr. Ali Parsa, Founder & CEO of Babylon Health. Credit: Babylon Health
April 16, 2019
With the ambitious mission to put an accessible and affordable health service in the hands of every person on earth, Babylon Health, an AI-powered smartphone app, was founded in January 2013 and launched to the public in April 2014. The company’s app, available on iOS and Android devices, allows users to book a video consultation with a doctor or a therapist, send photo or text messages to get...
Photo: Dr. James Creeden, Global Medical Director of Foundation Medicine. Credit: Foundation Medicine.
January 10, 2019
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company’s assay FoundationOne...